Your browser doesn't support javascript.
loading
Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia.
Chung, Goh Eun; Yim, Jeong Yoon; Kim, Donghee; Kwak, Min Sun; Yang, Jong In; Park, Boram; An, Seong Joon; Kim, Joo Sung.
Afiliación
  • Chung GE; Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.
  • Yim JY; Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea. yjy@snuh.org.
  • Kim D; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
  • Kwak MS; Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.
  • Yang JI; Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.
  • Park B; Department of Public Health Science, Seoul National University, Seoul, Korea.
  • An SJ; Korea University College of Medicine, Seoul, Korea.
  • Kim JS; Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.
J Korean Med Sci ; 35(22): e164, 2020 Jun 08.
Article en En | MEDLINE | ID: mdl-32508064
ABSTRACT

BACKGROUND:

Nonalcoholic fatty liver disease (NAFLD) is associated with a wide spectrum of metabolic abnormalities. This study aimed to evaluate whether NAFLD is associated with benign prostatic hyperplasia (BPH) independent of other risk factors.

METHODS:

A total of 3,508 subjects who underwent prostate and hepatic ultrasonography were enrolled. NAFLD was diagnosed and graded by ultrasonographic findings. BPH was defined by total prostate volume.

RESULTS:

The prevalence of BPH was significantly increased according to NAFLD severity (P < 0.001). The multivariate analysis showed that NAFLD was associated with a 22% increase in the risk of BPH (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.02-1.45). In non-obese subjects, NAFLD was associated with a 41% increase in the risk of BPH (OR, 1.41; 95% CI, 1.14-1.73), and an incremental increase in the risk of BPH according to NAFLD severity was pronounced (adjusted OR [95% CI], 1.32 [1.05-1.68] for mild NAFLD, 1.55 [1.15-2.10] for moderate to severe NAFLD vs. no NAFLD, P for trend = 0.004). However, in the obese population, the association of NAFLD in the risk of BPH was insignificant (P = 0.208).

CONCLUSION:

NAFLD is associated with an increased risk of BPH regardless of metabolic syndrome, especially in non-obese subjects. An incrementally increased risk of BPH according to NAFLD severity is prominent in non-obese subjects with NAFLD. Thus, physicians caring for non-obese patients with NAFLD may consider assessing the risk of BPH and associated urologic conditions.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Próstata / Hiperplasia Prostática / Enfermedad del Hígado Graso no Alcohólico / Hígado Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans / Male / Middle aged Idioma: En Revista: J Korean Med Sci Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Próstata / Hiperplasia Prostática / Enfermedad del Hígado Graso no Alcohólico / Hígado Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans / Male / Middle aged Idioma: En Revista: J Korean Med Sci Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article
...